Supernus Pharmaceuticals (SUPN)
(Delayed Data from NSDQ)
$33.65 USD
+1.26 (3.89%)
Updated Aug 13, 2024 03:59 PM ET
After-Market: $33.64 -0.01 (-0.03%) 7:16 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SUPN 33.65 +1.26(3.89%)
Will SUPN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SUPN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SUPN
Does Supernus (SUPN) Have the Potential to Rally 28.65% as Wall Street Analysts Expect?
Supernus (SUPN) Reports Q2 Earnings: What Key Metrics Have to Say
SUPN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Supernus Pharmaceuticals (SUPN) Misses Q2 Earnings Estimates
Select Medical (SEM) Q2 Earnings and Revenues Top Estimates
Do Options Traders Know Something About Supernus (SUPN) Stock We Don't?
Other News for SUPN
Piper Sandler Reaffirms Their Buy Rating on Supernus Pharmaceuticals (SUPN)
Supernus: Q2 Earnings Snapshot
Supernus Announces Second Quarter 2024 Financial Results
Supernus Pharmaceuticals, Inc. (SUPN) Q2 2024 Earnings Call Transcript
Here is the next potential market catalyst